Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Knegtering, R. Articles by van den Bosch, R. J. Search for Related Content PubMed Citation Articles by Knegtering, R. Articles by van den Bosch, R. J. Neuroendocrinology Atypical Neuroleptics

Predominant Role of the 9-Hydroxy Metabolite of Risperidone in Elevating Blood Prolactin Levels

OBJECTIVE: The atypical antipsychotic risperidone significantly raises plasma prolactin levels in patients, but clozapine, olanzapine, and quetiapine do not. The differences in neuroendocrine response may be connected with the metabolism of the medications. The authors examined the contributory role of risperidone’s active metabolite 9-hydroxy-risperidone by measuring plasma concentrations of risperidone, 9-hydroxy-risperidone, and prolactin. METHOD: Blood samples taken from 25 patients with psychotic disorders following 6 weeks of treatment with risperidone (mean dose=3 mg/day) were examined. Mean plasma concentrations of risperidone, 9-hydroxy-risperidone, and prolactin were 4.6, 19.4, and 49.3 ng/ml, respectively. RESULTS: The oral dose of risperidone correlated significantly with plasma concentrations of risperidone, 9-hydroxy-risperidone, active moiety, and prolactin. The plasma concentration of 9-hydroxy-risperidone, but not of risperidone, correlated significantly with increases in plasma prolactin. CONCLUSIONS: These data suggest that the 9-hydroxy metabolite plays a predominant role in risperidone’s effect on prolactin release.

This article has been cited by other articles:

				E. L. Breden, M. T. Liu, and S. R. Dean Metabolic and Cardiac Side Effects of Second-generation Antipsychotics: What Every Clinician Should Know Journal of Pharmacy Practice, October 1, 2009; 22(5): 478 - 488. [Abstract] [PDF]

				J. de Leon, N. B. Sandson, and K. L. Cozza A Preliminary Attempt to Personalize Risperidone Dosing Using Drug-Drug Interactions and Genetics: Part II Psychosomatics, July 1, 2008; 49(4): 347 - 361. [Full Text] [PDF]

				C. Dolder, M. Nelson, and Z. Deyo Paliperidone for schizophrenia Am. J. Health Syst. Pharm., March 1, 2008; 65(5): 403 - 413. [Abstract] [Full Text] [PDF]

				P. Fitzgerald and T. G Dinan Prolactin and dopamine: What is the connection? A Review Article J Psychopharmacol, March 1, 2008; 22(2_suppl): 12 - 19. [Abstract] [PDF]

				C. Bushe, M. Shaw, and R. C Peveler A review of the association between antipsychotic use and hyperprolactinaemia J Psychopharmacol, March 1, 2008; 22(2_suppl): 46 - 55. [Abstract] [PDF]

				L. Wang, L. Yu, A.-P. Zhang, C. Fang, J. Du, N.-F. Gu, S.-Y. Qin, G.-Y. Feng, X.-W. Li, Q.-H. Xing, et al. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia J Psychopharmacol, November 1, 2007; 21(8): 837 - 842. [Abstract] [PDF]

				A. Parashar, A. Varma, and B. Sharp Risperidone as Galactagogue? J Hum Lact, May 1, 2007; 23(2): 143 - 143. [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2005 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us